
Enlivex Seeks Shareholder Approval for $800M Crypto-Backed Financing
Enlivex, a Nasdaq-listed biotech company, is asking shareholders to approve up to $800 million in financing tied to the RAIN crypto token, which could dilute existing shares by up to 951%. The funds are primarily for crypto treasury purposes, with only a small portion earmarked for its Allocetra product.



















